<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pseudofolliculitis barbae</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pseudofolliculitis barbae</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pseudofolliculitis barbae</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Beth G Goldstein, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Adam O Goldstein, MD, MPH</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert P Dellavalle, MD, PhD, MSPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Cindy Owen, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew F Alexis, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 27, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pseudofolliculitis barbae (pseudofolliculitis of the beard), often colloquially referred to as "razor bumps," "shave bumps," or "ingrown hairs," is a common cutaneous condition that develops as a result of the removal of facial hair. Pseudofolliculitis barbae most frequently occurs in association with shaving and results from an inflammatory response to the cutaneous entrapment of recently cut, short hairs.</p><p>Pseudofolliculitis barbae typically presents with firm papules and pustules in the beard area  (<a class="graphic graphic_picture graphicRef51138 graphicRef63934 graphicRef69365" href="/z/d/graphic/51138.html" rel="external">picture 1A-C</a>). Postinflammatory hyperpigmentation, secondary bacterial infection, scarring, and keloid formation are potential complications  (<a class="graphic graphic_picture graphicRef51138 graphicRef96384" href="/z/d/graphic/51138.html" rel="external">picture 1A, 1D</a>).</p><p>The pathogenesis, diagnosis, and management of pseudofolliculitis barbae will be reviewed here  (<a class="graphic graphic_algorithm graphicRef134581" href="/z/d/graphic/134581.html" rel="external">algorithm 1</a>). Infectious folliculitis is reviewed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/103297.html" rel="external">"Infectious folliculitis"</a>.)</p><p></p><p class="headingAnchor" id="H1015817"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>As a condition associated with the removal of facial hair, pseudofolliculitis barbae is most prevalent in postpubertal males, with a predilection for populations with naturally curly hair [<a href="#rid1">1</a>]. In one study in the United States military, where a clean-shaven appearance is a component of military grooming standards, pseudofolliculitis barbae was detected in 45 percent of 50 Black males hospitalized for other indications, a rate considered to be much higher than the prevalence in White military service members [<a href="#rid2">2-4</a>]. Pseudofolliculitis barbae can also occur in females who remove facial hair and in association with frequent facial shaving in transfeminine individuals [<a href="#rid5">5</a>]. (See <a class="local">'Pathogenesis'</a> below.)</p><p class="headingAnchor" id="H2"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Although shaving is commonly associated with pseudofolliculitis barbae, other hair removal techniques (eg, plucking, waxing) may result in the development of this condition [<a href="#rid6">6</a>].</p><p>The clinical findings of pseudofolliculitis result from a cutaneous, inflammatory reaction against hair that has penetrated the interfollicular skin. This may occur through two mechanisms: extrafollicular and transfollicular penetration of the skin.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extrafollicular penetration </strong>– Extrafollicular penetration describes entry of the distal end of a hair into the interfollicular skin after it has already exited the follicular orifice  (<a class="graphic graphic_figure graphicRef87582" href="/z/d/graphic/87582.html" rel="external">figure 1</a>) [<a href="#rid6">6</a>]. This occurs when the distal end of a hair comes in contact with the surface of the skin. Shaving contributes to extrafollicular penetration by creating short, sharp-ended hairs that are capable of penetrating the skin.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transfollicular penetration </strong>– Transfollicular penetration occurs when the distal end of a hair penetrates the dermis prior to exiting the follicular orifice  (<a class="graphic graphic_figure graphicRef87583" href="/z/d/graphic/87583.html" rel="external">figure 2</a>) [<a href="#rid6">6</a>]. This event has been postulated to result from shaving techniques that result in retraction of the cut edge of the hair into the follicle, which can occur when the skin is stretched during shaving. Another theory is that the use of double-edged or multiple-edged razors may contribute to transfollicular penetration. The first razor edge pulls the hair upward, and the subsequent razor edge cuts the hair, resulting in retraction of the cut hair into the skin after shaving [<a href="#rid6">6</a>].</p><p></p><p>After entry into the interfollicular skin, the distal end of the hair may penetrate 2 to 3 mm into the dermis [<a href="#rid7">7</a>]. Eventually, continued hair growth leads to the spontaneous release of the embedded distal tip of the hair; this usually occurs within three to six weeks [<a href="#rid7">7,8</a>].</p><p>The predominance of pseudofolliculitis barbae in Black individuals is considered attributable to the prevalence of tightly curled hair in this population. The ends of tightly curled hair have a greater tendency to curve back towards the surface of the skin [<a href="#rid9">9</a>]. In addition, in individuals with tightly curled hair, the hair follicle sits at an oblique angle to the skin, which may contribute to the formation of sharp-tipped hairs during shaving [<a href="#rid6">6</a>]. One study identified a defect in a hair follicle keratin gene (<em>K6hf</em>) as a potential additional risk factor for this condition [<a href="#rid9">9</a>]. (See <a class="local">'Epidemiology'</a> above.)</p><p class="headingAnchor" id="H3"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Papules and pustules in sites of hair removal are the characteristic lesions of pseudofolliculitis barbae:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin lesions</strong> – The 2 to 5 mm, firm papules may be skin colored, erythematous, or hyperpigmented  (<a class="graphic graphic_picture graphicRef51138 graphicRef63934 graphicRef69365" href="/z/d/graphic/51138.html" rel="external">picture 1A-C</a>). Loops of hair emerging from the follicular orifice and re-entering the skin may be visible on the skin surface  (<a class="graphic graphic_picture graphicRef76686" href="/z/d/graphic/76686.html" rel="external">picture 2</a>). New papules may develop one to two days following an inciting shave [<a href="#rid3">3</a>]. Individual papules may persist for several weeks, until resolving after spontaneous or intentional freeing of embedded hair.</p><p></p><p class="bulletIndent1">Pustules may develop as a result of a sterile, acute, inflammatory response to embedded hair or as a manifestation of secondary infection [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Distribution</strong> – The extent of involvement varies widely, from patients with fewer than a dozen papules and pustules to patients with more than 100 lesions. The anterior neck, mandible, cheeks, and chin are the most common sites for involvement. Mustache and sideburn regions are typically spared [<a href="#rid7">7</a>]. Individuals who remove hair from sites such as the axilla, pubic area, and legs may develop pseudofolliculitis in these areas [<a href="#rid6">6,10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptoms and complications</strong> – Pruritus is common, and scratching can lead to bacterial superinfection. Hyperpigmentation or keloidal scarring may develop at sites of involvement in susceptible patients  (<a class="graphic graphic_picture graphicRef51138 graphicRef96384" href="/z/d/graphic/51138.html" rel="external">picture 1A, 1D</a>). (See <a class="local">'Complications'</a> below.)</p><p></p><p class="headingAnchor" id="H2752688358"><span class="h1">HISTOPATHOLOGY</span><span class="headingEndMark"> — </span>Histopathologic findings of pseudofolliculitis barbae include [<a href="#rid6">6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Intraepidermal neutrophils</p><p class="bulletIndent1"><span class="glyph">●</span>Foci of abscess formation in the dermis</p><p class="bulletIndent1"><span class="glyph">●</span>Granulomatous inflammation with foreign-body giant cells surrounding the tip of penetrating hairs</p><p></p><p class="headingAnchor" id="H87492034"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of pseudofolliculitis barbae is made based upon the history and physical findings. In general, a skin biopsy is not necessary.</p><p class="headingAnchor" id="H3720141174"><span class="h2">History and physical examination</span><span class="headingEndMark"> — </span>The patient history should include a review of the patient's hair removal practices and any observed associations between lesion development and hair removal. Expected physical examination findings include skin-colored, erythematous, or hyperpigmented papules and/or pustules limited to sites of prior terminal hair removal  (<a class="graphic graphic_picture graphicRef51138 graphicRef63934 graphicRef69365" href="/z/d/graphic/51138.html" rel="external">picture 1A-C</a>). Dermoscopic examination facilitates the visualization of characteristic embedded hairs  (<a class="graphic graphic_picture graphicRef76686" href="/z/d/graphic/76686.html" rel="external">picture 2</a>). (See <a class="local">'Clinical features'</a> above.)</p><p class="headingAnchor" id="H87492276"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of pseudofolliculitis barbae includes other conditions that may result in papules or pustules in areas of terminal hair growth. Examples include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bacterial folliculitis </strong>– Bacterial folliculitis usually presents as an acute condition with pustules and erythematous papules as the primary features  (<a class="graphic graphic_picture graphicRef62930 graphicRef62916" href="/z/d/graphic/62930.html" rel="external">picture 3A-B</a>). This contrasts with the chronic course and firm papules characteristic of pseudofolliculitis barbae. Cultures are useful for diagnosing bacterial folliculitis. In pseudofolliculitis barbae, cultures are usually negative or demonstrate normal skin flora in the absence of secondary infection [<a href="#rid6">6,8,11</a>]. (See  <a class="medical medical_review" href="/z/d/html/103297.html" rel="external">"Infectious folliculitis", section on 'Bacterial folliculitis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Traumatic folliculitis </strong>– Traumatic folliculitis describes transient inflammation of the hair follicle due to irritation from shaving too closely [<a href="#rid7">7</a>]. Patients present with perifollicular, erythematous papules and excoriations. Unlike pseudofolliculitis barbae, the condition usually subsides rapidly (within a few days) if shaving is discontinued.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tinea barbae </strong>– Dermatophyte infections involving the beard area are referred to as "tinea barbae." Patients may present with pustules; inflammatory papules and nodules; or scaly, erythematous plaques  (<a class="graphic graphic_picture graphicRef117243 graphicRef87000" href="/z/d/graphic/117243.html" rel="external">picture 4A-B</a>). The detection of fungal forms on a potassium hydroxide preparation or, rarely, a punch biopsy confirms the diagnosis. (See  <a class="medical medical_review" href="/z/d/html/103297.html" rel="external">"Infectious folliculitis", section on 'Dermatophytic folliculitis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acne keloidalis nuchae </strong>– Acne keloidalis nuchae is a hair and scalp disorder that may present with dome-shaped papules, pustules, and keloidal plaques on the occipital scalp  (<a class="graphic graphic_picture graphicRef87490" href="/z/d/graphic/87490.html" rel="external">picture 5</a>). The location of acne keloidalis on the scalp distinguishes this condition from pseudofolliculitis barbae. (See  <a class="medical medical_review" href="/z/d/html/15684.html" rel="external">"Acne keloidalis nuchae: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cutaneous sarcoidosis </strong>– Cutaneous sarcoidosis may present with a variety of manifestations, including firm papules or plaques that may be skin colored, yellow-brown, red-brown, violaceous, or hypopigmented  (<a class="graphic graphic_picture graphicRef73271 graphicRef69405" href="/z/d/graphic/73271.html" rel="external">picture 6A-B</a>). Unlike pseudofolliculitis barbae, embedded hairs are not a feature of cutaneous sarcoidosis, and lesions may be seen outside of the beard area. (See  <a class="medical medical_review" href="/z/d/html/13762.html" rel="external">"Cutaneous manifestations of sarcoidosis", section on 'Specific lesions'</a>.)</p><p></p><p class="headingAnchor" id="H4"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Few randomized trials have evaluated interventions for pseudofolliculitis barbae. The approach to management is primarily guided by clinical experience  (<a class="graphic graphic_algorithm graphicRef134581" href="/z/d/graphic/134581.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H664592452"><span class="h2">Overview</span><span class="headingEndMark"> — </span>The primary approach to therapy for pseudofolliculitis barbae consists of interventions to minimize entry of hair into the interfollicular skin, which is considered the major contributory factory to pseudofolliculitis barbae. The most effective intervention is the permanent discontinuation of shaving or other hair removal practices that contribute to the condition. (See <a class="local">'Patients for whom hair regrowth is acceptable'</a> below.)</p><p>However, occupational requirements, cultural values, and individual preferences prevent many patients from discontinuing hair removal indefinitely. For these patients, adjusting hair removal practices and incorporating topical therapy may help to improve control of the condition [<a href="#rid1">1,12</a>]. Laser hair removal is an option when these interventions are insufficient. (See <a class="local">'Patients for whom hair regrowth is not acceptable'</a> below and <a class="local">'Refractory disease'</a> below.)</p><p class="headingAnchor" id="H4199324271"><span class="h2">Patients for whom hair regrowth is acceptable</span><span class="headingEndMark"> — </span>Discontinuing the inciting cause of pseudofolliculitis barbae (eg, shaving, hair waxing, or hair plucking) and allowing the hair to remain at a length that makes penetration of the skin unlikely is the treatment of choice for pseudofolliculitis barbae  (<a class="graphic graphic_algorithm graphicRef134581" href="/z/d/graphic/134581.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H1015941"><span class="h3">Cessation of the inciting hair removal practice</span><span class="headingEndMark"> — </span>Depending on the severity of the condition, marked improvement in papules and pustules is usually noted within one to six months after ceasing hair removal [<a href="#rid6">6</a>]. Associated hyperpigmentation may take several months or longer to resolve. (See <a class="local">'Hyperpigmentation'</a> below.)</p><p>Patients may continue to groom the beard with scissors or an electric clipper. We suggest initially trimming the hair to a length of no less than 0.5 cm. Trials of shorter trim lengths can be performed after the patient attains lesion clearance.</p><p>Pseudofolliculitis may continue to progress during the first few weeks after the discontinuation of shaving due to the continued embedding of previously shaved hairs in the skin [<a href="#rid7">7,8</a>]. In the interim, the distal tips of visible, embedded hairs may be carefully dislodged by the patient with a toothpick or sterile needle. Hair should not be plucked from the follicle because doing so may cause additional irritation [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H134141424"><span class="h3">Treatment of acute lesions</span><span class="headingEndMark"> — </span>Low-potency topical corticosteroids may be helpful for reducing inflammation. Patients with highly inflamed lesions may benefit from intralesional corticosteroid injections. (See <a class="local">'Treatment of acute lesions'</a> below.)</p><p>Secondary infection should be treated with appropriate antibiotic therapy. (See <a class="local">'Secondary infection'</a> below.)</p><p class="headingAnchor" id="H2220084965"><span class="h2">Patients for whom hair regrowth is not acceptable</span><span class="headingEndMark"> — </span>Therapy for these patients involves short-term cessation of the inciting hair removal process (if possible), adjustments to hair removal methods, and anti-inflammatory therapy for acutely inflamed lesions  (<a class="graphic graphic_algorithm graphicRef134581" href="/z/d/graphic/134581.html" rel="external">algorithm 1</a>). In addition, long-term adjunctive treatment with topical antimicrobial agents and topical retinoids is often incorporated based upon limited data that suggest benefit in pseudofolliculitis barbae. (See <a class="local">'Short-term cessation of hair removal'</a> below and <a class="local">'Adjusting hair removal methods'</a> below and <a class="local">'Treatment of acute lesions'</a> below and <a class="local">'Adjunctive topical therapy'</a> below.)</p><p>Laser hair removal is an option for patients who fail to improve with these measures or prefer to proceed directly to this procedure as a long-term solution. (See <a class="local">'Refractory disease'</a> below.)</p><p class="headingAnchor" id="H3392830290"><span class="h3">Short-term cessation of hair removal</span><span class="headingEndMark"> — </span>When feasible, we encourage patients who are unable to permanently cease shaving to discontinue shaving until the condition improves (usually one to six months). Subsequently, changes in hair removal practices that may reduce the risk for recurrent pseudofolliculitis can be implemented. Patients who are unable to discontinue hair removal for this transient period can implement such measures immediately. (See <a class="local">'Adjusting hair removal methods'</a> below.)</p><p class="headingAnchor" id="H1308206979"><span class="h3">Adjusting hair removal methods</span><span class="headingEndMark"> — </span>Changes that may be helpful include adjustments to the shaving procedure and replacement of razor use with electric clippers or depilatories. The relative efficacy of these interventions is unclear; thus, selection among these measures is based upon patient preference. If a particular intervention does not yield improvement, one of the other approaches may be implemented  (<a class="graphic graphic_algorithm graphicRef134581" href="/z/d/graphic/134581.html" rel="external">algorithm 1</a>). (See <a class="local">'Shave procedure'</a> below and <a class="local">'Electric clippers'</a> below and <a class="local">'Chemical depilatories'</a> below.)</p><p class="headingAnchor" id="H1016168"><span class="h4">Shave procedure</span><span class="headingEndMark"> — </span>Clinical experience suggests that adjustments to the shaving routine, particularly preshave and postshave interventions, can be useful for pseudofolliculitis barbae. In the authors' experience, the incorporation of moisture before shaving has seemed particularly beneficial:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incorporation of moisture</strong> – The application of generous amounts of a highly lubricating shaving cream or gel for 5 to 10 minutes prior to shaving softens the hair and may help to reduce the formation of sharp hair tips during shaving. Application of warm compresses prior to shaving is an alternative approach [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Freeing of embedded hairs</strong> – Gentle washing of the beard area in a circular motion with a mildly abrasive cloth, sponge, or shaving brush for a few minutes daily may help to free embedded hairs [<a href="#rid6">6,13,14</a>]. Some authors have advocated using a magnifying mirror to identify embedded hairs, after which the embedded distal tips can be dislodged with a toothpick or sterile needle [<a href="#rid6">6,15</a>]. Plucking of hairs from the follicle should be avoided since this may lead to follicular inflammation and the subsequent growth of hair that penetrates the follicular wall [<a href="#rid7">7,8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Razor choice, shave direction, and shave frequency</strong> – Shaving in the direction of hair growth (ie, "with the grain") and reducing the frequency of shaving are sometimes advised. However, the efficacy of these approaches is unproven, and some authors suggest otherwise [<a href="#rid1">1,16,17</a>]. Avoidance of stretching of the skin during shaving and use of a razor with a skin guard has also been suggested [<a href="#rid13">13,18</a>]. Additional study is necessary to clarify preferred shave methods.</p><p></p><p class="bulletIndent1">One 12-week trial in which 90 patients with pseudofolliculitis barbae were randomly assigned to one of three treatment groups (shaving two to three times per week with a three-blade razor and standard products [cleanser, moisturizer, shaving gel], shaving daily with a five-blade razor and standard products, or shaving daily with a five-blade razor and advanced products) did not find significant differences among the three groups in outcomes of papule or pustule counts or investigator-assessed response to treatment [<a href="#rid17">17</a>].</p><p></p><p class="headingAnchor" id="H1015962"><span class="h4">Electric clippers</span><span class="headingEndMark"> — </span>Electric clippers can be used to shave hair in a manner that leaves the remaining hair at a greater length than razor shaves. Patients are encouraged to leave the remaining hair at a length of at least 1 mm to reduce the risk of lesion recurrence [<a href="#rid6">6</a>]. The stubbled appearance associated with residual short hairs may not be acceptable to some patients [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H1015969"><span class="h4">Chemical depilatories</span><span class="headingEndMark"> — </span>Clinical experience suggests some patients with pseudofolliculitis barbae improve when use of chemical depilatories replaces shaving. Chemical depilatories contain substances such as barium sulfide or calcium thioglycolate and remove hair by inducing the lysis of disulfide bonds in hair [<a href="#rid8">8</a>]. Hair removal with chemical depilatories tends to leave the distal ends of hairs with soft, brush-like tips rather than the sharp tips produced by shaving [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/z/d/html/1589.html" rel="external">"Removal of unwanted hair", section on 'Depilation'</a>.)</p><p>Chemical depilatory creams are usually applied to the skin for several minutes. Long hair in the treatment area should be clipped prior to use.</p><p>Irritation is a potential side effect of depilatories, and some patients are unable to tolerate these products on facial skin [<a href="#rid19">19</a>]. Patients should test the product on a nonfacial area and follow the site for irritation for 48 hours prior to facial use [<a href="#rid7">7</a>]. If significant irritation occurs, the product should not be used. Limiting the frequency of use to every other day or less may help to minimize irritation [<a href="#rid2">2,6</a>].</p><p class="headingAnchor" id="H2788461215"><span class="h3">Treatment of acute lesions</span><span class="headingEndMark"> — </span>Clinical experience suggests low-potency topical corticosteroids (group 6 or 7) are helpful for inflamed lesions  (<a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">table 1</a>) [<a href="#rid7">7</a>].</p><p>Topical corticosteroids are applied to inflamed lesions once or twice daily. Due to the potential for adverse effects on the skin, the treatment course is usually limited to less than three to four weeks on a particular area. An intralesional corticosteroid injection (eg, <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">triamcinolone</a> acetonide in a concentration of 2 to 3 mg/mL) is an alternative approach for larger, highly inflamed papules [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/z/d/html/5565.html" rel="external">"Topical corticosteroids: Use and adverse effects", section on 'Adverse effects'</a> and  <a class="medical medical_review" href="/z/d/html/5568.html" rel="external">"Intralesional corticosteroid injection"</a>.)</p><p>Oral tetracyclines (eg, subantimicrobial doses of <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>) are occasionally incorporated for patients with marked inflammation based upon anti-inflammatory benefit observed in other cutaneous disorders [<a href="#rid1">1,12,20</a>]. However, data to confirm efficacy of this approach are lacking.</p><p>Secondary infection should be treated with appropriate antibiotic therapy. (See <a class="local">'Secondary infection'</a> below.)</p><p class="headingAnchor" id="H4100963744"><span class="h3">Adjunctive topical therapy</span><span class="headingEndMark"> — </span>Data are limited on the efficacy of other medical therapies for pseudofolliculitis barbae. The most common adjunctive medical therapies for pseudofolliculitis barbae are topical antimicrobials (eg, <a class="drug drug_general" data-topicid="8811" href="/z/d/drug information/8811.html" rel="external">benzoyl peroxide</a> with or without <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a>) and topical retinoids (eg, tretinoin, <a class="drug drug_general" data-topicid="9352" href="/z/d/drug information/9352.html" rel="external">adapalene</a>)  (<a class="graphic graphic_algorithm graphicRef134581" href="/z/d/graphic/134581.html" rel="external">algorithm 1</a>). Further studies are necessary to clarify the efficacy of these agents. We usually incorporate these drugs in an attempt to achieve additional benefit.</p><p>Combination products containing both an antimicrobial and a topical retinoid can simplify the application regimen  (<a class="graphic graphic_table graphicRef56087" href="/z/d/graphic/56087.html" rel="external">table 2</a>). If tolerance is a concern or the presentation is mild, an alternative approach is to start with an antimicrobial (eg, <a class="drug drug_general" data-topicid="8811" href="/z/d/drug information/8811.html" rel="external">benzoyl peroxide</a> with or without <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a>) or retinoid, with subsequent addition of the second agent, if needed.</p><p>Continued treatment with these therapies is generally necessary for patients who respond if the inciting hair removal process is continued. In our experience, topical glycolic acid can be used as an alternative to a topical retinoid for maintenance of improvement:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical antimicrobials </strong>– Since pseudofolliculitis barbae is not an infectious condition, authors have disagreed on the indications for antimicrobial therapy. While some authors have primarily limited use to the setting of secondary infection [<a href="#rid7">7,15</a>], others have used these agents routinely based upon the idea that antibiotics may reduce skin flora that may aggravate inflammation or lead to secondary infection [<a href="#rid6">6,15,21</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8811" href="/z/d/drug information/8811.html" rel="external">Benzoyl peroxide</a> 2.5 to 6% is commonly used alone or in conjunction with a topical antibiotic, such as <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> 1% or <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a> 2%. Long-term use of topical antibiotics in the absence of benzoyl peroxide is not advised based upon concern for promoting antibiotic resistance [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1">A 10-week, randomized trial comparing the efficacy of a gel containing 5% <a class="drug drug_general" data-topicid="8811" href="/z/d/drug information/8811.html" rel="external">benzoyl peroxide</a> and 1% <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> with a vehicle gel in males using a specialized razor for pseudofolliculitis barbae suggests that antimicrobial therapy may accelerate improvement [<a href="#rid22">22</a>]. The reduction in lesion counts was greater in the active treatment group than in the placebo group at two, four, or six weeks after treatment. However, the difference between the groups was no longer statistically significant at week 10.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical retinoids </strong>– Topical retinoids, such as tretinoin, <a class="drug drug_general" data-topicid="9352" href="/z/d/drug information/9352.html" rel="external">adapalene</a>, or <a class="drug drug_general" data-topicid="9665" href="/z/d/drug information/9665.html" rel="external">tazarotene</a>, are applied to the affected region once daily in the evening. Starting with a lower concentration of a specific retinoid and/or an application frequency of every other night to every third night may help to minimize retinoid-induced skin irritation. (See  <a class="medical medical_review" href="/z/d/html/42.html" rel="external">"Acne vulgaris: Overview of management", section on 'Skin of color'</a>.)</p><p></p><p class="bulletIndent1">Two small, uncontrolled studies have documented clinical improvement in patients treated with daily application of <a class="drug drug_general" data-topicid="10014" href="/z/d/drug information/10014.html" rel="external">topical tretinoin</a> for several weeks, one of which involved the use of tretinoin in combination with a low-potency topical corticosteroid [<a href="#rid11">11,23</a>]. The rationale for a benefit of topical retinoids in pseudofolliculitis is uncertain; some authors have postulated that retinoids may improve follicular hyperkeratosis, which might contribute to the development of the condition [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1">Topical retinoid therapy may also accelerate improvement of hyperpigmentation. (See <a class="local">'Hyperpigmentation'</a> below and  <a class="medical medical_review" href="/z/d/html/95847.html" rel="external">"Postinflammatory hyperpigmentation", section on 'Topical retinoids'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glycolic acid</strong> – Topical glycolic acid products, such as glycolic acid 10% lotion, can be applied daily to the beard area. Two small, randomized trials support benefit of twice-daily application of 8% buffered glycolic acid for improving lesions of pseudofolliculitis barbae [<a href="#rid24">24</a>]. In addition, a trial in which 20 patients with pseudofolliculitis barbae were randomly assigned to up to five treatments with either a chemical peel with glycolic acid and <a class="drug drug_general" data-topicid="10296" href="/z/d/drug information/10296.html" rel="external">trichloroacetic acid</a> or a neodymium-doped yttrium aluminum garnet (Nd:YAG) laser found clinical improvement with both therapies, with laser therapy the most effective therapy [<a href="#rid25">25</a>]. Similar to topical retinoids, the mechanism of benefit in pseudofolliculitis barbae is unclear. (See <a class="local">'Laser hair removal'</a> below.)</p><p></p><p class="headingAnchor" id="H3500597724"><span class="h2">Refractory disease</span><span class="headingEndMark"> — </span>Patients who want or need to continue hair removal but fail to respond to first-line interventions may benefit from laser hair removal  (<a class="graphic graphic_algorithm graphicRef134581" href="/z/d/graphic/134581.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H1015976"><span class="h3">Laser hair removal</span><span class="headingEndMark"> — </span>Laser hair removal works through selective destruction of hair follicles and results in a reduction in the density and thickness of hair. Multiple treatment sessions are usually required to achieve a major reduction in hair growth because only a minority of hair follicles are destroyed during each treatment. Limited data suggest that the addition of topical eflornithine may be beneficial (see  <a class="medical medical_review" href="/z/d/html/1589.html" rel="external">"Removal of unwanted hair", section on 'Laser and intense pulsed light'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment principles</strong> – Since melanin is the follicular component targeted by hair removal lasers, patients with darkly pigmented hairs are the best candidates for this procedure. The treatment is poorly effective for white or gray hairs. (See  <a class="medical medical_review" href="/z/d/html/13648.html" rel="external">"Principles of laser and intense pulsed light for cutaneous lesions", section on 'Large versus small structures'</a> and  <a class="medical medical_review" href="/z/d/html/1589.html" rel="external">"Removal of unwanted hair", section on 'Laser and intense pulsed light'</a>.)</p><p></p><p class="bulletIndent1">Multiple lasers have demonstrated benefit for the treatment of pseudofolliculitis barbae, including long-pulsed Nd:YAG [<a href="#rid26">26-31</a>], diode [<a href="#rid32">32-34</a>], alexandrite [<a href="#rid35">35</a>], and ruby [<a href="#rid36">36</a>] lasers. As an example, in an open study in which 37 male patients with primarily mild pseudofolliculitis barbae had a 15 x 15 mm area in the submental region treated with one session with a long-pulsed Nd:YAG laser, examination 90 days after treatment revealed that mean papule counts were lower in the treated sites than in adjacent control sites (1.0±1.36 versus 6.9±5.25, respectively) [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1">Lasers should be selected carefully to minimize risk for adverse effects. Long wavelength lasers, such as the Nd:YAG laser, are generally a safer option for patients with highly pigmented skin [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Precautions</strong> – Risks of laser hair removal include transient or permanent, pigmentary changes; blistering; and scarring. The risk for pigmentary abnormalities is greatest in individuals with highly pigmented skin. Performing a test spot in an inconspicuous area may reduce the risk for disfiguring side effects by allowing the clinician to adjust laser settings appropriately prior to treatment.</p><p></p><p class="bulletIndent1">Patients should consider the permanent effects of laser hair removal; future hair regrowth is inhibited.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjunctive </strong><strong>eflornithine</strong> – Eflornithine is a topical agent used most commonly for the treatment of unwanted facial hair. The drug slows hair growth by inhibiting ornithine decarboxylase and is applied to areas of hair growth twice daily. Small, randomized trials suggest topical eflornithine may help to accelerate improvement in patients receiving laser therapy [<a href="#rid27">27,31</a>].</p><p></p><p class="bulletIndent1">In a split-face, randomized trial, 27 male patients with pseudofolliculitis barbae were treated with a long-pulsed Nd:YAG laser every 4 weeks for 16 weeks [<a href="#rid27">27</a>]. In addition, the patients applied eflornithine 13.9% cream to one side of the face and a placebo cream to the other side of the face twice daily. Although greater improvement in papular lesions was noted on the side of the face treated with eflornithine at every study time point, excellent results were attained in both groups, and the clinical difference in improvement in papular lesions was negligible after 16 weeks. A trial that compared twice-daily eflornithine therapy with Nd:YAG laser therapy given every four weeks and combination Nd:YAG laser and eflornithine therapy in 40 patients with pseudofolliculitis barbae supports superiority of combination therapy for improving inflammatory papules at 16 weeks [<a href="#rid31">31</a>]. (See <a class="local">'Other therapies'</a> below.)</p><p></p><p class="headingAnchor" id="H1998223642"><span class="h2">Other therapies</span><span class="headingEndMark"> — </span>Additional treatments that have been used for pseudofolliculitis barbae include eflornithine and photodynamic therapy. Electrolysis as an alternative to laser hair removal generally is not recommended:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical </strong><strong>eflornithine</strong> – Although the use of this agent has been advocated by some authors [<a href="#rid7">7,37,38</a>], study data on the efficacy of twice-daily application of eflornithine for pseudofolliculitis barbae are limited.</p><p></p><p class="bulletIndent1">A randomized trial (n = 40) that compared treatment with eflornithine alone with treatment with an Nd:YAG laser alone and with eflornithine and laser combination therapy supports benefit [<a href="#rid31">31</a>]. The trial found improvement in inflammatory papules in all three groups after 16 weeks, with combination therapy as the most effective intervention. The degree of improvement decreased in all groups during a 12-week, treatment-free, follow-up period.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Photodynamic therapy</strong> – Photodynamic therapy was proposed as a potential treatment based upon a case report describing benefit in a patient with refractory staphylococcal folliculitis barbae and pseudofolliculitis barbae [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Electrolysis/thermolysis</strong> – Electrolysis for permanent removal of beard hairs is generally not recommended for pseudofolliculitis barbae since it is painful, tedious, and often unsuccessful [<a href="#rid6">6</a>]. Exacerbation of pseudofolliculitis barbae is also a concern because failure of the electrolysis needle to reach the hair bulb of a curved hair follicle could theoretically result in an increased risk for subsequent transfollicular penetration during regrowth [<a href="#rid6">6</a>] (see <a class="local">'Pathogenesis'</a> above). Hyperpigmentation at sites of needle insertion and scarring are additional potential adverse effects of electrolysis. (See  <a class="medical medical_review" href="/z/d/html/1589.html" rel="external">"Removal of unwanted hair", section on 'Electrolysis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hormonal therapy</strong> – Some female patients with pseudofolliculitis barbae have hormonal abnormalities contributing to facial hair, suggesting hormonal therapy could be beneficial [<a href="#rid20">20</a>]. The effects of antiandrogenic therapy in female patients with pseudofolliculitis barbae have not been studied.</p><p></p><p class="headingAnchor" id="H194131250"><span class="h1">COMPLICATIONS</span><span class="headingEndMark"> — </span>Hyperpigmentation, keloids, and secondary infection are potential complications of pseudofolliculitis barbae.</p><p class="headingAnchor" id="H1070776073"><span class="h2">Hyperpigmentation</span><span class="headingEndMark"> — </span>Postinflammatory hyperpigmentation commonly occurs in sites of pseudofolliculitis barbae  (<a class="graphic graphic_picture graphicRef51138" href="/z/d/graphic/51138.html" rel="external">picture 1A</a>). Topical treatments such as <a class="drug drug_general" data-topicid="8539" href="/z/d/drug information/8539.html" rel="external">hydroquinone</a>, topical retinoids, alpha-hydroxy or polyhydroxy (glycolic or lactic) acid lotions or polyhydroxy acid (lactobionic acid)-containing lotions, <a class="drug drug_general" data-topicid="9038" href="/z/d/drug information/9038.html" rel="external">azelaic acid</a>, kojic acid, and chemical peels can be helpful for accelerating improvement in the hyperpigmentation associated with this condition [<a href="#rid15">15</a>]. The treatment of postinflammatory hyperpigmentation is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/95847.html" rel="external">"Postinflammatory hyperpigmentation", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H4257224683"><span class="h2">Keloids</span><span class="headingEndMark"> — </span>Keloidal scarring may occur in susceptible patients and can become extensive in some patients  (<a class="graphic graphic_picture graphicRef96384" href="/z/d/graphic/96384.html" rel="external">picture 1D</a>). Achieving control of pseudofolliculitis barbae is critical in these patients to minimize additional scarring. The treatment of existing keloids is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/5569.html" rel="external">"Keloids and hypertrophic scars"</a>.)</p><p class="headingAnchor" id="H2560434322"><span class="h2">Secondary infection</span><span class="headingEndMark"> — </span>Fluctuant lesions, purulent drainage, and worsening pain suggest the possibility of secondary infection. Appropriate management includes performance of cultures and administration of antibiotic therapy.</p><p class="headingAnchor" id="H3862918770"><span class="h1">PSYCHOSOCIAL AND OCCUPATIONAL IMPACT</span><span class="headingEndMark"> — </span>The discomfort and disfigurement associated with pseudofolliculitis barbae can negatively impact self-esteem and quality of life [<a href="#rid13">13</a>]. In addition, societal expectations and employment conditions that favor a "clean-shaven" appearance place individuals with pseudofolliculitis barbae at risk for career limitations and discrimination. The disproportionate medical and administrative effects of shaving requirements on Black military personnel has been a long-standing issue of concern in the United States military [<a href="#rid2">2-4</a>].</p><p>Places of employment that require shaving should consider the negative health effects of continued hair removal in patients with pseudofolliculitis barbae. Flexibility in hair grooming standards is essential for the optimal care of patients with pseudofolliculitis barbae.</p><p>Documentation of clinician support may be helpful for patients at risk for dismissal from a job or other negative career effects. This may include communication of the following principles:</p><p class="bulletIndent1"><span class="glyph">●</span>Pseudofolliculitis barbae is a chronic, inflammatory skin condition that is caused by hair removal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pseudofolliculitis barbae can result in physical discomfort, scarring, disfigurement, and infection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Discontinuation of contributory hair removal practices (eg, shaving) is the most effective treatment for pseudofolliculitis barbae.</p><p></p><p class="headingAnchor" id="H865943"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Pseudofolliculitis barbae is a cutaneous, inflammatory disorder that results from hair removal (eg, shaving, waxing, or plucking). The disorder occurs most frequently in the beard area of postpubertal males with naturally curly hair. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – Pseudofolliculitis barbae reflects an inflammatory reaction to hair that penetrates the interfollicular skin. Regrowing hairs penetrate the skin after shaving or other methods of removal. Shaving may contribute to sharp-tipped hairs, increasing the risk for penetration. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Pseudofolliculitis barbae presents as 2 to 5 mm papules and pustules in sites of hair removal  (<a class="graphic graphic_picture graphicRef51138 graphicRef63934 graphicRef69365" href="/z/d/graphic/51138.html" rel="external">picture 1A-C</a>). The papules may be skin colored, erythematous, or hyperpigmented. Loops of hair emerging from the follicular orifice and re-entering the skin may be visible on the skin surface  (<a class="graphic graphic_picture graphicRef76686" href="/z/d/graphic/76686.html" rel="external">picture 2</a>). The anterior neck, mandible, cheeks, and chin are the most common sites for involvement. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1">Postinflammatory hyperpigmentation, keloidal scarring, and secondary infection are potential complications  (<a class="graphic graphic_picture graphicRef51138 graphicRef96384" href="/z/d/graphic/51138.html" rel="external">picture 1A, 1D</a>). (See <a class="local">'Complications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – A diagnosis of pseudofolliculitis barbae is made based upon the history of hair removal and the recognition of consistent physical findings. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial management</strong> – The feasibility of adjustments to hair removal practices influences the approach to treatment  (<a class="graphic graphic_algorithm graphicRef134581" href="/z/d/graphic/134581.html" rel="external">algorithm 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>If cessation of close hair removal is feasible</strong> – The most effective therapy for pseudofolliculitis barbae is the permanent cessation of close hair removal and allowing the hair to remain at a length that reduces the risk of recurrence (at least 0.5 cm initially). Discontinuation of shaving often leads to improvement in pseudofolliculitis barbae within a few months. (See <a class="local">'Patients for whom hair regrowth is not acceptable'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>If cessation of close hair removal is not feasible</strong> – A multifaceted approach is taken for patients who cannot permanently cease close hair removal, including:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Short-term cessation of close hair removal</strong> – When feasible, patients should discontinue close hair removal until the condition improves (usually one to six months). Subsequently, adjustments to hair removal techniques that may reduce the risk for recurrent pseudofolliculitis can be implemented. (See <a class="local">'Short-term cessation of hair removal'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Adjustments to hair removal techniques</strong> – Preshave and postshave interventions, such as the routine incorporation of moisture and freeing of embedded hairs, may be beneficial for patients who must continue shaving. Transitioning from shaving to electric clippers or chemical depilatories may lead to improvement in some patients. (See <a class="local">'Adjusting hair removal methods'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Adjunctive medical therapy</strong> – We suggest a topical antimicrobial agent and a topical retinoid as adjunctive treatment (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Options for topical antimicrobial therapy include <a class="drug drug_general" data-topicid="8811" href="/z/d/drug information/8811.html" rel="external">benzoyl peroxide</a> with or without <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> or <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a>. (See <a class="local">'Adjunctive topical therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment of acutely inflamed lesions</strong> – For acutely inflamed lesions, we suggest low-potency topical corticosteroids (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Intralesional corticosteroid injection is an alternative for larger, highly inflamed papules. (See <a class="local">'Treatment of acute lesions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refractory disease</strong> – For patients who want or need to continue with hair removal but do not improve with initial interventions, we suggest laser hair removal rather than other therapies  (<a class="graphic graphic_algorithm graphicRef134581" href="/z/d/graphic/134581.html" rel="external">algorithm 1</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). The addition of topical eflornithine to laser therapy may be beneficial. (See <a class="local">'Refractory disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Psychosocial and occupational effects</strong> – Pseudofolliculitis barbae can negatively impact self-esteem and quality of life. Cessation of hair removal may place patients at risk for repercussions in the workplace. Providing support for the cessation of hair removal can be helpful for patients. (See <a class="local">'Psychosocial and occupational impact'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Nussbaum D, Friedman A. Pseudofolliculitis Barbae: A Review of Current Treatment Options. J Drugs Dermatol 2019; 18:246.</a></li><li><a class="nounderline abstract_t">Coquilla BH, Lewis CW. Management of pseudofolliculitis barbae. Mil Med 1995; 160:263.</a></li><li><a class="nounderline abstract_t">Tshudy MT, Cho S. Pseudofolliculitis Barbae in the U.S. Military, a Review. Mil Med 2021; 186:e52.</a></li><li><a class="nounderline abstract_t">Alexander AM, Delph WI. Pseudofolliculitis barbae in the military. A medical, administrative and social problem. J Natl Med Assoc 1974; 66:459.</a></li><li><a class="nounderline abstract_t">Yeung H, Kahn B, Ly BC, Tangpricha V. Dermatologic Conditions in Transgender Populations. Endocrinol Metab Clin North Am 2019; 48:429.</a></li><li><a class="nounderline abstract_t">Perry PK, Cook-Bolden FE, Rahman Z, et al. Defining pseudofolliculitis barbae in 2001: a review of the literature and current trends. J Am Acad Dermatol 2002; 46:S113.</a></li><li><a class="nounderline abstract_t">Kelly AP. Pseudofolliculitis barbae and acne keloidalis nuchae. Dermatol Clin 2003; 21:645.</a></li><li><a class="nounderline abstract_t">KLIGMAN AM, STRAUSS JS. Pseudofolliculitis of the beard. AMA Arch Derm 1956; 74:533.</a></li><li><a class="nounderline abstract_t">Winter H, Schissel D, Parry DA, et al. An unusual Ala12Thr polymorphism in the 1A alpha-helical segment of the companion layer-specific keratin K6hf: evidence for a risk factor in the etiology of the common hair disorder pseudofolliculitis barbae. J Invest Dermatol 2004; 122:652.</a></li><li><a class="nounderline abstract_t">DeMaria AL, Flores M, Hirth JM, Berenson AB. Complications related to pubic hair removal. Am J Obstet Gynecol 2014; 210:528.e1.</a></li><li><a class="nounderline abstract_t">Kligman AM, Mills OH Jr. Pseudofolliculitis of the beard and topically applied tretinoin. Arch Dermatol 1973; 107:551.</a></li><li><a class="nounderline abstract_t">Ogunbiyi A. Pseudofolliculitis barbae; current treatment options. Clin Cosmet Investig Dermatol 2019; 12:241.</a></li><li><a class="nounderline abstract_t">Alexis A, Heath CR, Halder RM. Folliculitis keloidalis nuchae and pseudofolliculitis barbae: are prevention and effective treatment within reach? Dermatol Clin 2014; 32:183.</a></li><li><a class="nounderline abstract_t">Cowley K, Vanoosthuyze K. Insights into shaving and its impact on skin. Br J Dermatol 2012; 166 Suppl 1:6.</a></li><li><a class="nounderline abstract_t">Quarles FN, Brody H, Johnson BA, et al. Pseudofolliculitis barbae. Dermatol Ther 2007; 20:133.</a></li><li><a class="nounderline abstract_t">Gray J, McMichael AJ. Pseudofolliculitis barbae: understanding the condition and the role of facial grooming. Int J Cosmet Sci 2016; 38 Suppl 1:24.</a></li><li><a class="nounderline abstract_t">Daniel A, Gustafson CJ, Zupkosky PJ, et al. Shave frequency and regimen variation effects on the management of pseudofolliculitis barbae. J Drugs Dermatol 2013; 12:410.</a></li><li><a class="nounderline abstract_t">Alexander AM. Evaluation of a foil-guarded shaver in the management of pseudofolliculitis barbae. Cutis 1981; 27:534.</a></li><li><a class="nounderline abstract_t">Kindred C, Oresajo CO, Yatskayer M, Halder RM. Comparative evaluation of men's depilatory composition versus razor in black men. Cutis 2011; 88:98.</a></li><li><a class="nounderline abstract_t">Nguyen TA, Patel PS, Viola KV, Friedman AJ. Pseudofolliculitis barbae in women: a clinical perspective. Br J Dermatol 2015; 173:279.</a></li><li><a class="nounderline abstract_t">Chu T. Pseudofolliculitis barbae. Practitioner 1989; 233:307.</a></li><li><a class="nounderline abstract_t">Cook-Bolden FE, Barba A, Halder R, Taylor S. Twice-daily applications of benzoyl peroxide 5%/clindamycin 1% gel versus vehicle in the treatment of pseudofolliculitis barbae. Cutis 2004; 73:18.</a></li><li><a class="nounderline abstract_t">Halder RM. The role of retinoids in the management of cutaneous conditions in blacks. J Am Acad Dermatol 1998; 39:S98.</a></li><li><a class="nounderline abstract_t">Perricone NV. Treatment of pseudofolliculitis barbae with topical glycolic acid: a report of two studies. Cutis 1993; 52:232.</a></li><li><a class="nounderline abstract_t">Amer A, Elsayed A, Gharib K. Evaluation of efficacy and safety of chemical peeling and long-pulse Nd:YAG laser in treatment of pseudofolliculitis barbae. Dermatol Ther 2021; 34:e14859.</a></li><li><a class="nounderline abstract_t">Ross EV, Cooke LM, Timko AL, et al. Treatment of pseudofolliculitis barbae in skin types IV, V, and VI with a long-pulsed neodymium:yttrium aluminum garnet laser. J Am Acad Dermatol 2002; 47:263.</a></li><li><a class="nounderline abstract_t">Xia Y, Cho S, Howard RS, Maggio KL. Topical eflornithine hydrochloride improves the effectiveness of standard laser hair removal for treating pseudofolliculitis barbae: a randomized, double-blinded, placebo-controlled trial. J Am Acad Dermatol 2012; 67:694.</a></li><li><a class="nounderline abstract_t">Schulze R, Meehan KJ, Lopez A, et al. Low-fluence 1,064-nm laser hair reduction for pseudofolliculitis barbae in skin types IV, V, and VI. Dermatol Surg 2009; 35:98.</a></li><li><a class="nounderline abstract_t">Weaver SM 3rd, Sagaral EC. Treatment of pseudofolliculitis barbae using the long-pulse Nd:YAG laser on skin types V and VI. Dermatol Surg 2003; 29:1187.</a></li><li><a class="nounderline abstract_t">Ross EV, Cooke LM, Overstreet KA, et al. Treatment of pseudofolliculitis barbae in very dark skin with a long pulse Nd:YAG laser. J Natl Med Assoc 2002; 94:888.</a></li><li><a class="nounderline abstract_t">Shokeir H, Samy N, Taymour M. Pseudofolliculitis barbae treatment: Efficacy of topical eflornithine, long-pulsed Nd-YAG laser versus their combination. J Cosmet Dermatol 2021; 20:3517.</a></li><li><a class="nounderline abstract_t">Smith EP, Winstanley D, Ross EV. Modified superlong pulse 810 nm diode laser in the treatment of pseudofolliculitis barbae in skin types V and VI. Dermatol Surg 2005; 31:297.</a></li><li><a class="nounderline abstract_t">Yamauchi PS, Kelly AP, Lask GP. Treatment of pseudofolliculitis barbae with the diode laser. J Cutan Laser Ther 1999; 1:109.</a></li><li><a class="nounderline abstract_t">Kauvar AN. Treatment of pseudofolliculitis with a pulsed infrared laser. Arch Dermatol 2000; 136:1343.</a></li><li><a class="nounderline abstract_t">Leheta TM. Comparative evaluation of long pulse Alexandrite laser and intense pulsed light systems for pseudofolliculitis barbae treatment with one year of follow up. Indian J Dermatol 2009; 54:364.</a></li><li><a class="nounderline abstract_t">Chui CT, Berger TG, Price VH, Zachary CB. Recalcitrant scarring follicular disorders treated by laser-assisted hair removal: a preliminary report. Dermatol Surg 1999; 25:34.</a></li><li><a class="nounderline abstract_t">Bridgeman-Shah S. The medical and surgical therapy of pseudofolliculitis barbae. Dermatol Ther 2004; 17:158.</a></li><li><a class="nounderline abstract_t">Garcia-Zuazaga J. Pseudofolliculitis barbae: review and update on new treatment modalities. Mil Med 2003; 168:561.</a></li><li><a class="nounderline abstract_t">Diernaes JE, Bygum A. Successful treatment of recalcitrant folliculitis barbae and pseudofolliculitis barbae with photodynamic therapy. Photodiagnosis Photodyn Ther 2013; 10:651.</a></li></ol></div><div id="topicVersionRevision">Topic 3323 Version 15.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30909328" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pseudofolliculitis Barbae: A Review of Current Treatment Options</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7659218" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Management of pseudofolliculitis barbae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33128565" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pseudofolliculitis Barbae in the U.S. Military, a Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4436875" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Pseudofolliculitis barbae in the military. A medical, administrative and social problem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31027550" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Dermatologic Conditions in Transgender Populations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11807473" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Defining pseudofolliculitis barbae in 2001: a review of the literature and current trends.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14717405" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Pseudofolliculitis barbae and acne keloidalis nuchae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13361541" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pseudofolliculitis of the beard.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15086549" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : An unusual Ala12Thr polymorphism in the 1A alpha-helical segment of the companion layer-specific keratin K6hf: evidence for a risk factor in the etiology of the common hair disorder pseudofolliculitis barbae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24486227" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Complications related to pubic hair removal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4697684" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Pseudofolliculitis of the beard and topically applied tretinoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31354326" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pseudofolliculitis barbae; current treatment options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24680005" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Folliculitis keloidalis nuchae and pseudofolliculitis barbae: are prevention and effective treatment within reach?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22385029" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Insights into shaving and its impact on skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17803606" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pseudofolliculitis barbae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27212468" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pseudofolliculitis barbae: understanding the condition and the role of facial grooming.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23652888" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Shave frequency and regimen variation effects on the management of pseudofolliculitis barbae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7238107" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Evaluation of a foil-guarded shaver in the management of pseudofolliculitis barbae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21916277" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Comparative evaluation of men's depilatory composition versus razor in black men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25557018" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pseudofolliculitis barbae in women: a clinical perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2587496" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Pseudofolliculitis barbae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15228130" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Twice-daily applications of benzoyl peroxide 5%/clindamycin 1% gel versus vehicle in the treatment of pseudofolliculitis barbae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9703134" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The role of retinoids in the management of cutaneous conditions in blacks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8261811" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Treatment of pseudofolliculitis barbae with topical glycolic acid: a report of two studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33559240" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Evaluation of efficacy and safety of chemical peeling and long-pulse Nd:YAG laser in treatment of pseudofolliculitis barbae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12140474" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Treatment of pseudofolliculitis barbae in skin types IV, V, and VI with a long-pulsed neodymium:yttrium aluminum garnet laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22226431" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Topical eflornithine hydrochloride improves the effectiveness of standard laser hair removal for treating pseudofolliculitis barbae: a randomized, double-blinded, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19076188" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Low-fluence 1,064-nm laser hair reduction for pseudofolliculitis barbae in skin types IV, V, and VI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14725660" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Treatment of pseudofolliculitis barbae using the long-pulse Nd:YAG laser on skin types V and VI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12408693" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Treatment of pseudofolliculitis barbae in very dark skin with a long pulse Nd:YAG laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33629488" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Pseudofolliculitis barbae treatment: Efficacy of topical eflornithine, long-pulsed Nd-YAG laser versus their combination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15841630" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Modified superlong pulse 810 nm diode laser in the treatment of pseudofolliculitis barbae in skin types V and VI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11357287" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Treatment of pseudofolliculitis barbae with the diode laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11074696" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Treatment of pseudofolliculitis with a pulsed infrared laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20101340" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Comparative evaluation of long pulse Alexandrite laser and intense pulsed light systems for pseudofolliculitis barbae treatment with one year of follow up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9935091" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Recalcitrant scarring follicular disorders treated by laser-assisted hair removal: a preliminary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15113283" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The medical and surgical therapy of pseudofolliculitis barbae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12901468" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pseudofolliculitis barbae: review and update on new treatment modalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24284123" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Successful treatment of recalcitrant folliculitis barbae and pseudofolliculitis barbae with photodynamic therapy.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
